C Fahrmayr1, J König1, D Auge1, M Mieth1, M F Fromm1. 1. Institute of Experimental and Clinical Pharmacology and Toxicology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
Abstract
BACKGROUND AND PURPOSE: The coordinate activity of hepatic uptake transporters [e.g. organic anion transporting polypeptide 1B1 (OATP1B1)], drug-metabolizing enzymes [e.g. UDP-glucuronosyltransferase 1A1 (UGT1A1)] and efflux pumps (e.g. MRP2) is a crucial determinant of drug disposition. However, limited data are available on transport of drugs (e.g. ezetimibe, etoposide) and their glucuronidated metabolites by human MRP2 in intact cell systems. EXPERIMENTAL APPROACH: Using monolayers of newly established triple-transfected MDCK-OATP1B1-UGT1A1-MRP2 cells as well as MDCK control cells, single- (OATP1B1) and double-transfected (OATP1B1-UGT1A1, OATP1B1-MRP2) MDCK cells, we therefore studied intracellular concentrations and transcellular transport after administration of ezetimibe or etoposide to the basal compartment. KEY RESULTS: Intracellular accumulation of ezetimibe was significantly lower in MDCK-OATP1B1-UGT1A1-MRP2 triple-transfected cells compared with all other cell lines. Considerably higher amounts of ezetimibe glucuronide were found in the apical compartment of MDCK-OATP1B1-UGT1A1-MRP2 monolayers compared with all other cell lines. Using HEK cells, etoposide was identified as a substrate of OATP1B1. Intracellular concentrations of etoposide equivalents (i.e. parent compound plus metabolites) were affected only to a minor extent by the absence or presence of OATP1B1/UGT1A1/MRP2. In contrast, apical accumulation of etoposide equivalents was significantly higher in monolayers of both cell lines expressing MRP2 (MDCK-OATP1B1-MRP2, MDCK-OATP1B1-UGT1A1-MRP2) compared with the single-transfected (OATP1B1) and the control cell line. CONCLUSIONS AND IMPLICATIONS: Ezetimibe glucuronide is a substrate of human MRP2. Moreover, etoposide and possibly also its glucuronide are substrates of MRP2. These data demonstrate the functional interplay between transporter-mediated uptake, phase II metabolism and export by hepatic proteins involved in drug disposition.
BACKGROUND AND PURPOSE: The coordinate activity of hepatic uptake transporters [e.g. organic anion transporting polypeptide 1B1 (OATP1B1)], drug-metabolizing enzymes [e.g. UDP-glucuronosyltransferase 1A1 (UGT1A1)] and efflux pumps (e.g. MRP2) is a crucial determinant of drug disposition. However, limited data are available on transport of drugs (e.g. ezetimibe, etoposide) and their glucuronidated metabolites by humanMRP2 in intact cell systems. EXPERIMENTAL APPROACH: Using monolayers of newly established triple-transfected MDCK-OATP1B1-UGT1A1-MRP2 cells as well as MDCK control cells, single- (OATP1B1) and double-transfected (OATP1B1-UGT1A1, OATP1B1-MRP2) MDCK cells, we therefore studied intracellular concentrations and transcellular transport after administration of ezetimibe or etoposide to the basal compartment. KEY RESULTS: Intracellular accumulation of ezetimibe was significantly lower in MDCK-OATP1B1-UGT1A1-MRP2 triple-transfected cells compared with all other cell lines. Considerably higher amounts of ezetimibe glucuronide were found in the apical compartment of MDCK-OATP1B1-UGT1A1-MRP2 monolayers compared with all other cell lines. Using HEK cells, etoposide was identified as a substrate of OATP1B1. Intracellular concentrations of etoposide equivalents (i.e. parent compound plus metabolites) were affected only to a minor extent by the absence or presence of OATP1B1/UGT1A1/MRP2. In contrast, apical accumulation of etoposide equivalents was significantly higher in monolayers of both cell lines expressing MRP2 (MDCK-OATP1B1-MRP2, MDCK-OATP1B1-UGT1A1-MRP2) compared with the single-transfected (OATP1B1) and the control cell line. CONCLUSIONS AND IMPLICATIONS: Ezetimibe glucuronide is a substrate of humanMRP2. Moreover, etoposide and possibly also its glucuronide are substrates of MRP2. These data demonstrate the functional interplay between transporter-mediated uptake, phase II metabolism and export by hepatic proteins involved in drug disposition.
Authors: Scott W Altmann; Harry R Davis; Li-Ji Zhu; Xiaorui Yao; Lizbeth M Hoos; Glen Tetzloff; Sai Prasad N Iyer; Maureen Maguire; Andrei Golovko; Ming Zeng; Luquan Wang; Nicholas Murgolo; Michael P Graziano Journal: Science Date: 2004-02-20 Impact factor: 47.728
Authors: James E Patrick; Teddy Kosoglou; Kathe L Stauber; Kevin B Alton; Stephen E Maxwell; Yali Zhu; Paul Statkevich; Robert Iannucci; Swapan Chowdhury; Melton Affrime; Mitchell N Cayen Journal: Drug Metab Dispos Date: 2002-04 Impact factor: 3.922
Authors: Anima Ghosal; Neil Hapangama; Yuan Yuan; Joana Achanfuo-Yeboah; Robert Iannucci; Swapan Chowdhury; Kevin Alton; James E Patrick; Shmuel Zbaida Journal: Drug Metab Dispos Date: 2004-03 Impact factor: 3.922
Authors: Kathrin Mandery; Krystyna Bujok; Ingrid Schmidt; Thomas Wex; Gerhard Treiber; Peter Malfertheiner; Tilman T Rau; Kerstin U Amann; Kay Brune; Martin F Fromm; Hartmut Glaeser Journal: J Pharmacol Exp Ther Date: 2009-10-20 Impact factor: 4.030
Authors: C Fahrmayr; J König; D Auge; M Mieth; K Münch; J Segrestaa; T Pfeifer; A Treiber; Mf Fromm Journal: Br J Pharmacol Date: 2013-05 Impact factor: 8.739
Authors: Annemieke J M Nieuweboer; Shuiying Hu; Chunshan Gui; Bruno Hagenbuch; Inge M Ghobadi Moghaddam-Helmantel; Alice A Gibson; Peter de Bruijn; Ron H J Mathijssen; Alex Sparreboom Journal: Cancer Res Date: 2014-04-22 Impact factor: 12.701
Authors: C D Drenberg; S W Paugh; S B Pounds; L Shi; S J Orwick; L Li; S Hu; A A Gibson; R C Ribeiro; J E Rubnitz; W E Evans; A Sparreboom; S D Baker Journal: Clin Pharmacol Ther Date: 2016-02-20 Impact factor: 6.875